Compare RLJ & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLJ | ANIP |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2011 | 1999 |
| Metric | RLJ | ANIP |
|---|---|---|
| Price | $11.42 | $75.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $7.83 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.8M | 326.9K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.26% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 0.12 | ★ 2.32 |
| Revenue | ★ $1,349,860,000.00 | $206,547,000.00 |
| Revenue This Year | $2.02 | $21.01 |
| Revenue Next Year | $2.54 | $17.59 |
| P/E Ratio | $95.67 | ★ $33.33 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $6.54 | $70.15 |
| 52 Week High | $12.89 | $99.50 |
| Indicator | RLJ | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 40.88 |
| Support Level | $10.86 | $74.33 |
| Resistance Level | $12.11 | $83.43 |
| Average True Range (ATR) | 0.39 | 2.55 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 32.81 | 17.30 |
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.